Thrombosis Research
Volume 126, Issue 3 , Pages e196-e200 , September 2010

In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves

  • Lars Maegdefessel

      Affiliations

    • Department of Medicine III at the University Hospital Haale (Saale), Martin-Luther-University Halle-Wittenberg, Germany
    • Corresponding Author InformationCorresponding author. Stanford University – School of Medicine, Division of Cardiovascular Medicine, 300 Pasteur Drive, Falk CVRB, Stanford, CA 94305 – 5406 USA. Tel.: +1 650 724 5075; fax: +1 650 725 1599.
    • Present address: Division of Cardiovascular Medicine, Stanford University – School of Medicine, Stanford, CA, USA.
    • ,
  • Torsten Linde

      Affiliations

    • Applied Medical Engineering at the Helmholtz Institute, RWTH Aachen University, Aachen, Germany
    • ,
  • Franziska Krapiec

      Affiliations

    • Department of Medicine III at the University Hospital Haale (Saale), Martin-Luther-University Halle-Wittenberg, Germany
    • ,
  • Kathrin Hamilton

      Affiliations

    • Applied Medical Engineering at the Helmholtz Institute, RWTH Aachen University, Aachen, Germany
    • ,
  • Ulrich Steinseifer

      Affiliations

    • Applied Medical Engineering at the Helmholtz Institute, RWTH Aachen University, Aachen, Germany
    • ,
  • Joanne van Ryn

      Affiliations

    • Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
    • ,
  • Uwe Raaz

      Affiliations

    • Department of Medicine III at the University Hospital Haale (Saale), Martin-Luther-University Halle-Wittenberg, Germany
    • ,
  • Michael Buerke

      Affiliations

    • Department of Medicine III at the University Hospital Haale (Saale), Martin-Luther-University Halle-Wittenberg, Germany
    • ,
  • Karl Werdan

      Affiliations

    • Department of Medicine III at the University Hospital Haale (Saale), Martin-Luther-University Halle-Wittenberg, Germany
    • ,
  • Axel Schlitt

      Affiliations

    • Department of Medicine III at the University Hospital Haale (Saale), Martin-Luther-University Halle-Wittenberg, Germany

Received 8 March 2010 ,Revised 15 June 2010 ,Accepted 16 June 2010.

References 

  1. Cannegieter SC, Torn M, Rosendaal FR. Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. J Intern Med. 1999;245:369–374
  2. Palareti G, Hirsh J, Legnani C, Manotti C, D'Angelo A, Pengo V, et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med. 2000;160:470–478
  3. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic SurgeonsBonow RO, Carabello BA, Kanu C, de Leon AC, Faxon DP, et al. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease. Circulation. 2006;114:84-231
  4. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al. Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease. Eur Heart J. 2007;28:230–268
  5. Hirsh J. Heparin. N Engl J Med. 1987;324:1565–1574
  6. Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med. 2000;160:229–236
  7. Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ. American College of Chest Physician. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:110–112
  8. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost. 2008;34:39–57
  9. Eriksson BI, Smith H, Yasothan U, Kirkpatrick P. Dabigatran etexilate. Nat Rev Drug Discov. 2008;7:557–558
  10. Eikelboom JE, Weitz JI. Dabigatran etexilate for prevention of venous thromboembolism. Thromb Haemost. 2009;101:2–4
  11. Dahl OE. Dabigatran etexilate: A new oral thrombin inhibitor. Therapy. 2008;5:1–11
  12. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178–2185
  13. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, et al. RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949–956
  14. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, et al. RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1–9
  15. Bellhouse BJ, Talbot C. The fluid mechanics of the aortic valve. J Fluid Mech. 1969;35:721–735
  16. Reul H, Vahlbruch M, Effert S. The Geometry of the Aortic Root in Health, at Valve Disease and after Valve Replacement. J Biomech. 1990;23:181–189
  17. Reul H, Talukter N. Heart valve mechanics. Quantitative Cardiovascular Studies. In:  Hwang NHC, et al. editor. Baltimore: University Park Press; 1979;p. 527–564
  18. Huang PY, Hellums JD. Aggregation and Disaggregation Kinetics of Human Blood Platelets: Part II. Shear-induced Platelet Aggregation. Biophys J. 1993;65:344–353
  19. Felfernig M, Blaicher A, Kettner SC, Felfernig D, Acimovic S, Kozek-Langenecker SA. Effects of temperature of partial thomboplastin time in heparinised plasma in vitro. Eur J Anesthesiol. 2001;18:467–470
  20. Maegdefessel L, Buerke M, Schubert S, Reindl I, Michel T, Hauroeder B, et al. Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study. Thromb Haemost. 2008;100:693–698
  21. Schlitt A, Hamilton K, Maegdefessel L, Dahm M, Theis C, Eichler M, et al. Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study. J Heart Valve Dis. 2006;15:809–814
  22. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98:155–162
  23. Dasi LP, Simon HA, Sucosky P, Yoganathan AP. Fluid mechanics of artificial heart valves. Clin Exp Pharmacol Physiol. 2009;36:225–237
  24. Zhang P, Yeo JH, Qian P, Hwang NH. Shear stress investigation across mechanical heart valve. ASAIO J. 2007;53:530–536
  25. Smith CJ, Vournakis JN, Demcheva M, Fischer TH. Differential effect of materials for surface hemostasis on red blood cell morphology. Microsc Res Tech. 2008;71:721–729
  26. Eikelboom JW, Weitz JI. A Replacement for Warfarin: The Search Continues. Circulation. 2007;116:131–133
  27. Ezekowitz MD. Anticoagulation Interruptus: Not Without Risk. Circulation. 2004;110:1518–1519
  28. Turpie AG. The top 4 advances in antithrombotic care in the last year. Thromb Res. 2008;S1:S2–S6
  29. Spyropoulos AC. Brave new world: the current and future use of novel anticoagulants. Thromb Res. 2008;S1:S29–S35
  30. Maegdefessel L, Linde T, Michel T, Hamilton K, Steinseifer U, Friedrich I, et al. Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves, results of an in vitro study. Thromb Haemost. 2009;101:1163–1169
  31. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. The RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361:1139–1151
  32. Herijgers P, Verhamme P. Improving the quality of anticoagulant therapy in patients with mechanical heart valves: what are we waiting for?. Eur Heart J. 2007;28:2424–2426

☆ The results of the study have been presented at the ISTH (International Society of Thrombosis and Haemostasis) Meeting 2009 in Boston (16.07.2009), the ESC (European Society of Cardiology) Meeting 2009 in Barcelona (31.08.2009), and the DGK (Deutsche Gesellschaft für Kardiologie) Meeting 2009 in Mannheim (18.04.2009).

PII: S0049-3848(10)00350-6

doi: 10.1016/j.thromres.2010.06.011

Thrombosis Research
Volume 126, Issue 3 , Pages e196-e200 , September 2010

Article Tools

* Image Usage & Resolution